Biotech firm unveils early data on pill that mimics exercise effects

Enveda, a five-year-old biotechnology company in Boulder, Colorado, released Phase 1 data for its experimental oral medication ENV-308. The drug is modeled on lactate phenylalanine, a small-molecule metabolite identified by Stanford scientists as capable of reducing appetite and lowering obesity in animal tests. ENV-308 is designed to preserve lean muscle mass, addressing a common drawback of existing weight-loss treatments that can cause muscle loss during repeated use.

Both the natural metabolite and the engineered compound influence leptin signaling, a hormone pathway that has been pursued for decades in obesity research. The company suggests that, pending successful clinical validation, ENV-308 would be the first pill to act as a leptin sensitizer, potentially offering weight-loss benefits without the gastrointestinal issues associated with GLP-1 drugs.